The Differences of Serum Metabolites Between Patients With Early-Stage Alzheimer's Disease and Mild Cognitive Impairment

Background: Mild cognitive impairment (MCI) is regarded as a transition phase between normal aging and Alzheimer's disease (AD). Identification of novel and non-invasive biomarkers that can distinguish AD at an early stage from MCI is warranted for therapeutic and support planning. The goal of...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Wei-Chieh, Huang, Wen-Yi, Tang, Hsiang-Yu, Cheng, Mei-Ling, Chen, Kuan-Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884031/
https://www.ncbi.nlm.nih.gov/pubmed/31824405
http://dx.doi.org/10.3389/fneur.2019.01223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884031/
https://www.ncbi.nlm.nih.gov/pubmed/31824405
http://dx.doi.org/10.3389/fneur.2019.01223

Ejemplares similares